

Jon Kroll Bjerregaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7702308/publications.pdf>

Version: 2024-02-01

39
papers

871
citations

706676

14
h-index

536525

29
g-index

40
all docs

40
docs citations

40
times ranked

2050
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 144, 72-80.	1.3	17
2	A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. <i>Acta Oncologica</i> , 2021, 60, 948-953.	0.8	2
3	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 158, 248-250.	1.3	0
4	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 176-184.	1.1	12
5	Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13219.	0.7	19
6	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	1.3	27
7	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , 2019, 115, 61-67.	1.3	11
8	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 573-578.	1.1	9
9	Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877703.	1.4	60
10	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 267-267.	0.8	0
11	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, e16249-e16249.	0.8	1
12	Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Clinical and Experimental Metastasis</i> , 2017, 34, 309-314.	1.7	55
13	S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. <i>Acta Oncologica</i> , 2017, 56, 46-51.	0.8	2
14	Automatic treatment planning facilitates fast generation of high-quality treatment plans for esophageal cancer. <i>Acta Oncologica</i> , 2017, 56, 1495-1500.	0.8	32
15	Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943-2012. <i>Acta Oncologica</i> , 2017, 56, 1763-1768.	0.8	9
16	Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016, 55, 40-45.	0.8	24
17	FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study. <i>Journal of Clinical Oncology</i> , 2016, 34, 408-408.	0.8	0
18	S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 153-153.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final Results.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15725-e15725.	0.8	1
20	Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. <i>Acta OncolÅ³gica</i> , 2015, 54, 447-453.	0.8	55
21	Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. <i>Clinical Colorectal Cancer</i> , 2015, 14, 170-176.	1.0	26
22	Efficacy and safety of S-1 and gemcitabine in an unselected Western cohort of patients with unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15258-e15258.	0.8	0
23	Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer. <i>Acta OncolÅ³gica</i> , 2014, 53, 385-391.	0.8	6
24	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 392.	3.8	380
25	A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 337-337.	0.8	4
26	In Reply to Parlak and Topkan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 6-7.	0.4	0
27	Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. <i>PLoS ONE</i> , 2013, 8, e67059.	1.1	28
28	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 164-164.	0.8	1
29	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4052-4052.	0.8	2
30	Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 909-915.	0.4	20
31	Selection, therapy, and outcome in an unselected population-based study of 604 patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 238-238.	0.8	0
32	Cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastroesophageal cancer (GEC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 101-101.	0.8	0
33	Biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastroesophageal cancer (GEC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e14517-e14517.	0.8	0
34	Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. <i>Acta OncolÅ³gica</i> , 2011, 50, 1250-1252.	0.8	6
35	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. <i>Gastric Cancer</i> , 2011, 14, 219-225.	2.7	21
36	Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. <i>Acta OncolÅ³gica</i> , 2011, 50, 574-577.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. <i>Acta Oncologica</i> , 2010, 49, 833-836.	0.8	9
38	Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2009, 92, 226-230.	0.3	17
39	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. <i>OncoTargets and Therapy</i> , 2009, 2, 17-27.	1.0	3